At a glance
- Originator Servier
- Class Anxiolytics
- Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 02 Sep 1998 No-Development-Reported for Anxiety disorders in France (Unknown route)
- 15 Feb 1996 New profile
- 15 Feb 1996 Preclinical development for Anxiety disorders in France (Unknown route)